

# Normal human monocytic cell line CRL9855 can be transformed into macrophages with very low concentrations of phorbol 12-myristate 13-acetate

Radu-Marian Marinescu<sup>1</sup>, Michel-Edwar Mickael<sup>2,3</sup>, Ana-Maria Enciu<sup>\*1,4</sup>

1 Carol Davila University of Medicine and Pharmacy, 050047 Bucharest, Romania

2 Department of Experimental Genomics, Institute of Animal Biotechnology and Genetics, Polish Academy of Science, Postępu 36A, 05-552 Jastrzebiec, Poland.

3 Department of Immunology, PM Forskningscentrum, 17854 Ekerö Stockholm, Sweden.

4 Victor Babes National Institute of Pathology, Biochemistry, 050096 Bucharest, Romania.

## Abstract

Monocytes are leukocytes that can differentiate into tissue macrophages and act in immune surveillance and tissue reconstruction. They are frequently used *in vitro* to study inflammatory response, lymphocyte activation, and phagocytosis. A widely used model is the *in vitro* differentiation of various monocytic cell lines including THP-1 and U937 using phorbol 12-myristate 13-acetate (PMA). These cell lines have various limitations because of their malignant background. Data available on utilizing normal human monocytes cell lines are scarce. Our study aims to identify the optimum concentration of PMA needed to maximize the number of adherent macrophages using the normal monocytic cell line SC. Using impedance readings and time-lapse microscopy, we determined that the optimum PMA concentration is 25ng/mL for 48 hrs. Using these optimized conditions, we were able to induce the formation of adherent and proliferating macrophages, which can be further used for morphology and functional studies.

## Key words:

CRL-9855, SC cell line, monocytes, PMA, differentiation protocol, macrophages.

## DOI

<https://www.doi.org/10.47570/joci.2022.005>

## \* Corresponding author:

ana.enciu@umfcd.ro

## List of symbols and abbreviations:

|        |   |  |
|--------|---|--|
| CMP    | – | common myeloid progenitor                        |
| GM-CSF | – | granulocyte-macrophage colony-stimulating factor |
| G-CSF  | – | granulocyte colony-stimulating factor            |
| LPS    | – | lipopolysaccharide                               |
| PMA    | – | phorbol 12-myristate 13-acetate                  |

## Introduction

Monocytes are part of the reticuloendothelial system, along with tissue-resident macrophages. Like most cells of the immune system (except for lymphocytes), monocytes originate from the multipotent common myeloid progenitor stem cell (CMP) from the bone marrow, under the influence of cytokines: GM-CSF (Granulocyte-macrophage colony-stimulating factor), G-CSF (granulocyte colony-stimulating), and IL-3. GM-CSF is produced by a large category of cells, like endothelial cells, T cells, macrophages, mast cells, and fibroblasts (Ross and Pawlina, 2020). Following differentiation into adult monocytes, they enter the bloodstream and migrate into tissues under the control of local growth factors, pro-inflammatory cytokines, and microbial products. Now, they can differentiate into local macrophages, such as osteoclasts, alveolar macrophages, or Kupffer cells (Ross and Pawlina, 2020). Monocytes are involved in various immune processes: they play a very important role during bacterial, protozoan, and viral infections, in cancer, atherosclerosis, and autoimmune diseases. For example, they can provide effective protection against infection with gram-negative bacteria, by interaction with lipopolysaccharide (LPS), a macromolecule found in the bacterial wall. Peripheral monocytes migrate to lymph nodes where they become antigen-presenting cells for CD4+ and CD8+ T cells, which can initiate adaptive immunity against pathogens, mainly via cytokine production (Bosshart and Heinzlmann, 2016a).

Due to their important role in immune responses, monocytes are frequently used as an *in vitro* model to study inflammatory response, lymphocyte activation,

and phagocytosis. There are several known cell lines, frequently reported in original articles, such as THP-1 or U937 cell lines. The THP-1 cell line is a human monocytic leukemia cell line, obtained from a patient who suffered from acute monocytic leukemia. THP-1 cells can start to adhere to culture plates and can be cultured *in vitro* to passage 25 and still keep their sensitivity and activity (Bosshart and Heinzlmann, 2016b). U937 is a pro-monocytic human myeloid leukemia cell line, isolated from a patient who suffered from histiocytic lymphoma. It can be used for exploration of the mechanisms behind the attachment of monocytes to the endothelium. Unlike THP-1, U937 can be used for a higher number of passages. It is important to know that these cell lines have some limitations because of their malignant background (Chanput, Peters and Wichers, 2015).

One main application of monocytic cell lines is their conversion into macrophages. The most common protocols used involve phorbol 12-myristate 13-acetate (PMA) (Daigneault et al., 2010a). It is very important to mention that, at first, PMA induces inhibition of cell growth. More exactly, it can inhibit the cell cycle at G1-phase via a complex mechanism which includes the modulation of the expression of some cell cycle regulators, initiated by the cellular generation of reactive oxygen species (Traore et al., 2005).

The mechanism through which PMA can act is through the activation of protein kinase C. An advantage of using PMA is that it is not dependent on receptors on the cell membrane and it is less time-critical, as its effects are sustained for at least 30 minutes.


As far as cell morphology goes, it has been proven that the number

of some organelles is different and the cytoplasm can expand (this modifies the ratio between cytoplasm and nucleus, favoring the cytoplasm). For example, cells treated with PMA followed by a period of 5 days resting in culture without PMA increased the number of lysosomes and mitochondria. Also, these cells are more resistant to apoptosis and the capacity of phagocytosis is higher, especially for latex beads (Daigneault et al., 2010b). It has been shown that PMA differentiation induces the expression of genes related to PI-3K signaling pathway and phagosomal pathway (Zeng et al., 2015). However, it has been reported that differences may exist between U937 and THP-1 in terms of phagocytic activity (Mendoza-Coronel and Castañón-Arreola, 2016), while THP-1 was similar in this respect to human circulating monocytes (Madhvi et al., 2019). These differences could be explained by numerous chromosomal aberrations (Adati et al., 2009), and mutations detected in THP-1 as well as U937 cells.

From this perspective, the optimum model would be primary culture of macrophages derived from patients' circulating monocytes. However, as patient sampling is not always available, a cell line from a normal genetic background could provide the best *in vitro* model. Such model is provided by SC cell line, obtained from immature monocytes, with no malignant characteristics (US Patent 5,447,861).

The data available regarding the PMA-induced differentiation protocol for this cell line is scarce. This cell line provides the benefit of normal background and may offer a different landscape during activation of inflammatory mechanisms compared to malignant cells.

**Fig.1**  
Phase-contrast images of PMA treated SC human monocytes at 24 and 48 hrs. Arrows indicate adhered cells. 20x magnification. Scale bar 100  $\mu$ m.



In literature, a limited number of studies have investigated the optimum conditions needed for PMA induced macrophage differentiation of this cell line (Wawrzynkiewicz et al., 2020) (Samie et al., 2016). Additionally, there is no consensus on the optimum starting concentration for this PMA differentiation protocol. Some articles report a nM concentration, whereas others, ng/mL. Either way, the working concentration ranges between 10-200 either nM or ng/mL. (Daigneault et al., 2010b)(Starr et al., 2018)(O'Mahony et al., 1998)(Park et al., 2007a). Also, in these studies a different number of cells is used, varying between  $5 \times 10^4$  and  $2 \times 10^6$  cells/ $\mu$ L.

Our study aims at investigating the optimum concentration of PMA


to achieve the maximum number of adherent macrophages using the normal monocytic cell line SC. Given the changes induced by PMA treatment, we followed a scale-down approach, starting from the highest concentration reported in the literature (200 ng/mL), to obtain the best result with minimum changes in cell proliferation status and offer a starting point for further research.

### Material and method

Cell culture and cell treatments. Normal human monocytes (ATCC-CRL-9855) were routinely maintained according to manufacturer's instructions in Iscove's Modified Dulbecco's Medium (IMDM) supplemented with 10% fetal bovine serum, 1% antibiotic, hypoxanthine (100 $\mu$ M) and thymidine (16

$\mu$ M) (HT supplement 100x) and 55  $\mu$ M beta-mercaptoethanol) in a 5% CO<sub>2</sub> incubator and 37°C. Cells were treated with PMA (Sigma Aldrich P1585), reconstituted in DMSO to a concentration of 1mg/mL (1st stock). Following the first utilization of one stock vial, a second stock solution was prepared (0.1 mg/mL) which was aliquoted in 10 $\mu$ L aliquots for single (or maximum 2) use. Working solutions were prepared by successive dilutions in 1.5 mL tubes, using complete cell medium. Each PMA

**Fig. 2.** Selected frames of time-lapse recordings of monocytes treated with 25 ng/mL PMA. Left panel includes 3 successive time-frames (steps 46-48, at 15 mins apart). Right panel is captured after 15 hrs of treatment with the same concentration. Arrowheads point at dead cells/cell fragments. Phase contrast, 20x. Scale bar 10  $\mu$ m.



solution was further diluted in-well, 1:1 with an equal volume of cell medium containing the desired number of cells. The final in-well working concentrations of PMA were 200 ng/mL, 100 ng/mL, 50 ng/mL, 25 ng/mL, 10 ng/mL and 5 ng/mL. 50 000 cells were plated in 24 wells plates and incubated for up to 72 hrs in decreasing concentrations of PMA. Images were captured every 24 hrs using a phase-contrast Evos microscope.

**Real-time impedance readings:** Cell adhesion and cell proliferation were assessed using RTCA DP platform (Agilent Technologies). They were trypsinized and seeded in E-16 plates at a density of 50000 cells/well, with or without PMA at indicated concentrations. Readings were collected every 5 mins for 24 hrs, followed by readings at 15 mins up to 92 hrs.

**Videomicroscopy:** 4 chambers 35mm dish (Ibdi,  $\mu$ -Dish 35 mm Quad - 80416) were seeded with 10000 cells/well and recorded every 15 mins for 48 hrs in a Biostation Incubator (Nikon). Post data analysis was performed using Biostation IM software (Nikon).

**Results**

Normal human monocytes require 48 hrs to adhere, at low concentrations of PMA.

Frequently, phenotype change is induced with either 200 nM or 200 ng/mL, therefore 200 ng/mL was the starting concentration of our study which corresponds to 324,24 nM (Table 1). 24 hrs were insufficient for cell adherence, although adhered cells could be occasionally observed. At 48 hrs adherent cells were observed for concentrations as low as 25 ng/mL (fig. 1).

Next, we were interested in defining the timeline of monocyte adherence, hence we performed a time-lapse recording of the modifications induced by various concentrations of PMA on monocyte phenotype (fig.2). We observed that at high concentrations (200,100 ng/mL) mitosis does not occur during the first 24-27 hrs, whereas for the low concentrations, cells begin to divide after the first 6-7 hrs of treatment (fig.2 left panel), albeit many cell deaths are also observed during the first 24 hrs (fig.2 right panel).

Finally, we were interested in quantifying the number of cells that adhered and can be further used for functional experiments. We chose to use the xCelligence real-time platform, which can record and quantify in real-time the contacts the cells make with the


**Table 1.** Correlation between various concentrations of PMA used in experimental approaches

| PMA (ng/mL) | PMA (nM) |
|-------------|----------|
| 200         | 324.24   |
| 100         | 162.12   |
| 50          | 81       |
| 25          | 40.5     |

plate bottom (fig3).

As expected, untreated cells recorded a very low index, whereas PMA treated cells displayed a reversed dose-dependent response. Of note, no significant change was observed between tested concentrations during the first 15 hrs. The cells treated with 200 ng/mL en-

**Fig.3.** Real-time impedance readings of PMA treated SC human monocytes. Each concentration was tested in triplicate, using 50000 cells/well. Graph lines represent impedance readings at every 15 mins  $\pm$  S.D for each reading.



tered a plateau around 24 hrs which lasted for at least another 24 hrs, then resumed proliferation at a slow rate. The appearance of this proliferation plateau decreased with decreased concentration. The lowest concentration allowed the proliferation of adhered cells up to 90 hrs.

### **Discussion**

Phenotype change of circulating monocytes in macrophages under PMA treatment is widely used in *in vitro* studies of inflammation and immune responses. However, there are two major issues regarding this protocol: the variety in PMA concentration and incubation time. More consistency in differentiation protocol is required (Park et al., 2007b). Also, cells with malignant background are frequently used, whereas normal human cell lines are less frequently reported or studied. We believe that for assessment of biocompatibility (e.g., toxicity, inflammation studies) a normal cell line would be a preferable choice over a tumor cell line. Therefore, we focused on a normal monocyte line, SC monocytes. This particular cell line is not well referenced in the literature – a search

on PubMed using” CRL-9855” retrieved only 3 results and we found an additional one using” SC cell line”. A search for” SC macrophages” or” SC monocytes was not very informative, as the name of the cell line (SC) was frequently omitted from the search. Of the four articles, only one reported the use of PMA at 20 ng/mL (Ribeiro et al., 2014). Our study also demonstrated that normal human monocytes can become adherent with low PMA concentrations, and this phenotype change does not affect cell proliferation. Scaling down PMA concentrations still induced cell adherence in our experimental setup, as soon as 24 hrs. However, for functional studies, especially cytokine assessment, a minimum number of cells is necessary to synthesize a minimum amount of protein detectable in various protein assays. In order to quantify cell number, we used impedance reading assay, which converts cell number into a measurable cell index. Low concentrations of PMA were correlated with the highest cellular index after 3 days of cell culture. As reported in the literature, PMA treatment induces a stop in G1 (Spano, Barni and Sciola,

2013), which is translated as a plateau in our impedance recordings. As observed, higher PMA concentrations induce a longer plateau, whereas at lower concentrations, the plateau phase is reduced and cell proliferation is resumed sooner. The rising of the index indicates that proliferating cells are still attached to the bottom of the plate. Videomicroscopy confirmed that the inhibition of cell cycle is shorter with lower concentrations of PMA and cells are resuming cell divisions faster, although failure of cell division and subsequent cell death was observed during the first 24 hrs. After 48 hrs, an adherent population of dividing cells is obtained, for further studies.

In conclusion, we demonstrated that normal human monocytes SC treatment with 25 ng/mL of PMA is a better option for phenotype change into adherent macrophages. As future line of investigation, the evaluation of the phenotype of the macrophages produced by our protocol could be a next step

### **Funding**

This work has been funded by the Romanian Ministry of Research and Innovation, CCCDI-UEFISCDI, in the framework of project PN-III-P1-1.2-PCCDI-2017-0062 (contract no. 58) and by a grant of the Ministry of Research, Innovation and Digitization, CNCS/CCCDI – UEFISCDI, project number PNIII.P2-2.1-PED-2019-3141, contract no 382/2020, within PNCDI III.

### **Competing interests/conflict of interests**

The authors declare no conflict of interest.

**References**

- Adati, N. et al.** (2009) 'High-resolution analysis of aberrant regions in autosomal chromosomes in human leukemia THP-1 cell line', *BMC Research Notes*, 2(1), p. 153. doi: 10.1186/1756-0500-2-153.
- Bosshart, H. and Heinzelmann, M.** (2016a) 'THP-1 cells as a model for human monocytes.', *Annals of translational medicine*, 4(21), p. 438. doi: 10.21037/atm.2016.08.53.
- Bosshart, H. and Heinzelmann, M.** (2016b) 'THP-1 cells as a model for human monocytes.', *Annals of translational medicine*, 4(21), p. 438. doi: 10.21037/atm.2016.08.53.
- Chanput, W., Peters, V. and Wichers, H.** (2015) 'THP-1 and U937 Cells', in *The Impact of Food Bioactives on Health*. Cham: Springer International Publishing, pp. 147–159. doi: 10.1007/978-3-319-16104-4\_14.
- Daigneault, M. et al.** (2010a) 'The Identification of Markers of Macrophage Differentiation in PMA-Stimulated THP-1 Cells and Monocyte-Derived Macrophages', *PLoS ONE*. Edited by T. M. Doherty, 5(1), p. e8668. doi: 10.1371/journal.pone.0008668.
- Daigneault, M. et al.** (2010b) 'The Identification of Markers of Macrophage Differentiation in PMA-Stimulated THP-1 Cells and Monocyte-Derived Macrophages', *PLoS ONE*. Edited by T. M. Doherty, 5(1), p. e8668. doi: 10.1371/journal.pone.0008668.
- Madhvi, A. et al.** (2019) 'Comparison of human monocyte derived macrophages and THP1-like macrophages as *in vitro* models for *M. tuberculosis* infection', *Comparative Immunology, Microbiology and Infectious Diseases*, 67, p. 101355. doi: 10.1016/j.cimid.2019.101355.
- Mendoza-Coronel, E. and Castañón-Arreola, M.** (2016) 'Comparative evaluation of *in vitro* human macrophage models for mycobacterial infection study', *Pathogens and Disease*. Edited by P. Brennan, 74(6), p. ftw052. doi: 10.1093/femspd/ftw052.
- O'Mahony, L. et al.** (1998) 'Quantitative intracellular cytokine measurement: age-related changes in proinflammatory cytokine production.', *Clinical and experimental immunology*, 113(2), pp. 213–9. doi: 10.1046/j.1365-2249.1998.00641.x.
- Park, E. K. et al.** (2007a) 'Optimized THP-1 differentiation is required for the detection of responses to weak stimuli', *Inflammation Research*, 56(1), pp. 45–50. doi: 10.1007/s00011-007-6115-5.
- Park, E. K. et al.** (2007b) 'Optimized THP-1 differentiation is required for the detection of responses to weak stimuli', *Inflammation Research*, 56(1), pp. 45–50. doi: 10.1007/s00011-007-6115-5.
- Ribeiro, L. C. et al.** (2014) 'Recombinant disintegrin targets  $\alpha(v)\beta(3)$  integrin and leads to mediator production', *Cell Adhesion & Migration*, 8(1), pp. 60–65. doi: 10.4161/cam.27698.
- Ross, M. H. and Pawlina, W.** (2020) 'The blood', in *Histology: A textbook and atlas*, p. 297.
- Samie, N. et al.** (2016) 'Novel piperazine core compound induces death in human liver cancer cells: possible pharmacological properties.', *Scientific reports*, 6, p. 24172. doi: 10.1038/srep24172.
- Spano, A., Barni, S. and Sciola, L.** (2013) 'PMA withdrawal in PMA-treated monocytic THP-1 cells and subsequent retinoic acid stimulation, modulate induction of apoptosis and appearance of dendritic cells.', *Cell proliferation*, 46(3), pp. 328–47. doi: 10.1111/cpr.12030.
- Starr, T. et al.** (2018) 'The phorbol 12-myristate-13-acetate differentiation protocol is critical to the interaction of THP-1 macrophages with *Salmonella Typhimurium*.', *PLoS one*, 13(3), p. e0193601. doi: 10.1371/journal.pone.0193601.
- Traore, K. et al.** (2005) 'Signal transduction of phorbol 12-myristate 13-acetate (PMA)-induced growth inhibition of human monocytic leukemia THP-1 cells is reactive oxygen dependent.', *Leukemia research*, 29(8), pp. 863–79. doi: 10.1016/j.leukres.2004.12.011.
- Wawrzynkiewicz, A. et al.** (2020) 'The Cytotoxicity and Genotoxicity of Three Dental Universal Adhesives-An *in vitro* Study.', *International journal of molecular sciences*, 21(11). doi: 10.3390/ijms21113950.
- Zeng, C. et al.** (2015) 'Pathways related to PMA-differentiated THP1 human monocytic leukemia cells revealed by RNA-Seq', *Science China Life Sciences*, 58(12), pp. 1282–1287. doi: 10.1007/s11427-015-4967-4.

